Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prognostic Value of Fibrosis-4 Index, Hepatic Biomarkers, and Plasma Acute-Phase Reactants in Critical Patients Undergoing Percutaneous Endoscopic Gastrostomy: A Retrospective Cohort Study.

Journal of clinical medicine·2026

Same author

Impact of Rifaximin, a Gut-Selective Antibiotic, on Gastric Intestinal Metaplasia: A Retrospective Study.

Journal of clinical medicine·2026

Same author

Coexistence of VLCAD deficiency and Hashimoto's thyroiditis: a rare case report.

BMC endocrine disorders·2026

Same author

Gastric Mucosal Atrophy and Serum Biomarker Alterations in Women with Endometriosis: A Case-Control Study.

Reproductive sciences (Thousand Oaks, Calif.)·2026

Same author

A comprehensive endoscopic and clinical evaluation of Cameron ulcers: Insights from a single-center cross-sectional experience.

Medicine·2026

Same author

Association of drug allergy history with Helicobacter pylori infection, duodenal eosinophil and mast cell counts in dyspeptic patients.

Medicine·2026

Search research articles

Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

Ursodeoxycholic acid induced generalized fixed drug eruption.

Hatice Uce Ozkol¹, Omer Calka, Ahmet Cumhur Dulger

¹Department of Dermatology, Faculty of Medicine .

Cutaneous and Ocular Toxicology

|October 24, 2013

Summary

Fixed drug eruption (FDE) is a rare drug allergy. This study reports a generalized FDE case linked to Ursodeoxycholic acid (UDCA) in a cholestatic patient, a first for this medication.

Keywords:

Bile acids generalized fixed drug eruption ursodeoxycholic acid

Related Experiment Videos

Last Updated: May 6, 2026

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

Area of Science:

Dermatology
Pharmacology
Hepatology

Background:

Fixed drug eruption (FDE) is a rare, recurrent drug allergy presenting with characteristic skin lesions.
Ursodeoxycholic acid (UDCA) is a primary treatment for cholestatic liver diseases.
Adverse reactions to UDCA typically include gastrointestinal issues and headaches.

Observation:

A 59-year-old male patient with cholestasis developed a generalized fixed drug eruption.
The FDE was temporally associated with the intake of Ursodeoxycholic acid (UDCA).
Previous literature documented only three cases of lichenoid reactions to UDCA.

Findings:

This case represents the first documented instance of generalized fixed drug eruption attributed to Ursodeoxycholic acid (UDCA).
The patient's clinical presentation and history strongly implicated UDCA as the causative agent.
The reaction manifested as widespread, sharply demarcated dusky red plaques.

Implications:

This finding expands the known spectrum of adverse drug reactions associated with Ursodeoxycholic acid (UDCA).
Clinicians should consider FDE in patients presenting with characteristic lesions after UDCA initiation.
Further pharmacovigilance is warranted to monitor for rare adverse events like FDE with UDCA use.